Evidence map›Paper›PMID 34853088›Full record

ArticleThe Journal of rheumatology2022

The Association of Tumor Necrosis Factor Inhibitor Use With Incident Hypertension in Ankylosing Spondylitis: Data From the PSOAS Cohort.

Jean W Liew, S Reza Jafarzadeh, Maureen Dubreuil, Susan R Heckbert, Stephen J Mooney, Matthew A Brown, Mariko L Ishimori, John D Reveille, Michael M Ward, Michael H Weisman and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Jean W LiewJ.W. Liew, MD, MS, S.R. Jafarzadeh, PhD, M. Dubreuil, MD, MSc, Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA; jwliew@bu.edu.ORCID 0000-0002-8104-2450
S Reza JafarzadehJ.W. Liew, MD, MS, S.R. Jafarzadeh, PhD, M. Dubreuil, MD, MSc, Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0002-1099-9175
Maureen DubreuilJ.W. Liew, MD, MS, S.R. Jafarzadeh, PhD, M. Dubreuil, MD, MSc, Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0002-6253-1515
Susan R HeckbertS.R. Heckbert, MD, PhD, Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, Seattle, Washington, USA.
Stephen J MooneyS.J. Mooney, PhD, Department of Epidemiology, University of Washington, Seattle, Washington, USA.
Matthew A BrownM.A. Brown, MBBS, MD, FRACP, FAHSM, FAA, King's College London and Guy's and St Thomas' NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, London, UK.
Mariko L IshimoriM.L. Ishimori, MD, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
John D ReveilleJ.D. Reveille, MD, Division of Rheumatology and Clinical Immunogenetics, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas, USA.
Michael M WardM.M. Ward, MD, MPH, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Michael H WeismanM.H. Weisman, MD, Division of Rheumatology, Cedars-Sinai Medical Center, and David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Lianne S GenslerL.S. Gensler, MD, Department of Medicine/Rheumatology, Russell Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, California, USA.
Boston University · USCedars-Sinai Medical Center · USUniversity of Washington · USKing's College London · GBNational Institutes of Health · USThe University of Texas Health Science Center at Houston · USUniversity of California, San Francisco · US

Funding

Research and Evaluation Support Core Unit (RESCU Core)P30AR072571 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Michael Paul Lavalley · 2019 to 2026
$6.9M
Dynamic Treatment Regimens of Physical Activity for Persons with OsteoarthritisR21AR074578 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI JAFARZADEH, S. REZA · 2019 to 2020
$411k
Effects of NSAIDs and non-NSAID Analgesics on Osteoarthritis OutcomesR03AG060272 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI JAFARZADEH, S. REZA · 2018 to 2019
$165k
NIAMS NIH HHS P30 AR072571NIAMS NIH HHS R21 AR074578NIA NIH HHS R03 AG060272
6 · The paper itself

Abstract

objectiveIndividuals with ankylosing spondylitis (AS) have a greater cardiovascular (CV) risk than those in the general population. The effect of tumor necrosis factor inhibitors (TNFis) on CV risk, including on the development of hypertension (HTN), remains unclear, with some data suggesting higher risk. We assessed the association of TNFi use with incident HTN in a longitudinal AS cohort.

methodsAdults with AS enrolled in a prospective cohort in 2002-2018 were examined every 4-6 months. TNFi use during the preceding 6 months was ascertained at each study visit. We defined HTN by patient-reported HTN, antihypertensive medication use, or, on 2 consecutive visits, systolic blood pressure (BP) ≥ 140 mmHg or diastolic BP ≥ 90 mmHg. We evaluated the association between TNFi use and the development of HTN with marginal structural models, estimated by inverse probability-of-treatment weighting, to account for time-dependent confounders and informative censoring. Potential confounders included age, sex, race, site, nonsteroidal antiinflammatory drug use, and disease activity.

resultsWe included 630 patients without baseline HTN and with at least 1 year of follow-up. Of these, 72% were male, mean age was 39 ± 13 years, and 43% used TNFi at baseline. On follow-up (median 5 yrs), 129 developed incident HTN and 163 started on TNFi during follow-up. TNFi use was not associated with incident HTN (adjusted HR 1.10, 95% CI 0.83-1.37).

conclusionIn our prospective AS cohort, TNFi use was not significantly associated with incident HTN.

Indexed as

Antirheumatic AgentsHypertensionSpondylitis, AnkylosingAdultCohort StudiesFemaleHumansMaleMiddle AgedProspective StudiesTreatment OutcomeTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsAntirheumatic AgentsTumor Necrosis Factor-alphaTumor Necrosis Factor Inhibitorsankylosing spondylitiscardiovascular diseasesspondyloarthropathy

Identifiers

PMID34853088
PMCPMC10404976
OpenAlexW3215582448

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.